Positive results for Titan antibody

Published: 29-Jun-2001


Phase II studies on Titan Pharmaceuticals' monoclonal antibody immunotherapy TriGem for the treatment of stage III melanoma have shown that it may improve patient survivial. The multicentre study showed improved survival and relapse-free survival rates after two years, and results appear even better if TriGem is administered in combination with a-interferon.

You may also like